Recently, progress in combination therapies of melanoma treatment have significantly addressed the limitation of vemurafenib alone, the most successful combination therapeutic regimen was dabrafenib (the second BRAF inhibitor approved by FDA) plus trametinib, which induced complete and partial responses in almost 70% of patients and prolonged median progression-free survival in several phase 3 clinical trials, approximately 3–5 months longer than single vemurafenib alone [13]. Here, BRAF is linked to melanoma.